120 related articles for article (PubMed ID: 9430866)
1. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers.
Scott MK; Mueller BA; Clark WR
Nephrol Dial Transplant; 1997 Dec; 12(12):2647-53. PubMed ID: 9430866
[TBL] [Abstract][Full Text] [Related]
2. Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.
Welage LS; Mason NA; Hoffman EJ; Odeh RM; Dombrouski J; Patel JA; Swartz RD
J Am Soc Nephrol; 1995 Oct; 6(4):1284-90. PubMed ID: 8589298
[TBL] [Abstract][Full Text] [Related]
3. A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear).
Allawati H; Dallas L; Nair S; Palmer J; Thaikandy S; Hutchison C
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32408589
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
Mason NA; Neudeck BL; Welage LS; Patel JA; Swartz RD
Clin Nephrol; 2003 Aug; 60(2):96-104. PubMed ID: 12940611
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an in vitro dialysis system to predict drug removal.
Hudson JQ; Comstock TJ; Feldman GM
Nephrol Dial Transplant; 2004 Feb; 19(2):400-5. PubMed ID: 14736965
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes.
DeSoi CA; Sahm DF; Umans JG
Am J Kidney Dis; 1992 Oct; 20(4):354-60. PubMed ID: 1415203
[TBL] [Abstract][Full Text] [Related]
7. CAHP-210 dialyzer influence on intra-dialytic vancomycin removal.
Lucksiri A; Scott MK; Mueller BA; Hamburger RJ; Sowinski KM
Nephrol Dial Transplant; 2002 Sep; 17(9):1649-54. PubMed ID: 12198218
[TBL] [Abstract][Full Text] [Related]
8. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes.
De Smet R; Dhondt A; Eloot S; Galli F; Waterloos MA; Vanholder R
Nephrol Dial Transplant; 2007 Jul; 22(7):2006-12. PubMed ID: 17468506
[TBL] [Abstract][Full Text] [Related]
9. Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities.
Meert N; Eloot S; Schepers E; Lemke HD; Dhondt A; Glorieux G; Van Landschoot M; Waterloos MA; Vanholder R
Nephrol Dial Transplant; 2011 Aug; 26(8):2624-30. PubMed ID: 21310741
[TBL] [Abstract][Full Text] [Related]
10. Effects of dialysis membrane on intradialytic vancomycin administration.
Scott MK; Macias WL; Kraus MA; Clark WR; Carfagna MA; Mueller BA
Pharmacotherapy; 1997; 17(2):256-62. PubMed ID: 9085316
[TBL] [Abstract][Full Text] [Related]
11. Removal of high-molecular-weight solutes during high-efficiency and high-flux haemodialysis.
Leypoldt JK; Cheung AK
Nephrol Dial Transplant; 1996 Feb; 11(2):329-35. PubMed ID: 8671788
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis.
Pollard TA; Lampasona V; Akkerman S; Tom K; Hooks MA; Mullins RE; Maroni BJ
Kidney Int; 1994 Jan; 45(1):232-7. PubMed ID: 8127014
[TBL] [Abstract][Full Text] [Related]
13. Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes.
Böhler J; Reetze-Bonorden P; Keller E; Kramer A; Schollmeyer PJ
Eur J Clin Pharmacol; 1992; 42(6):635-9. PubMed ID: 1623904
[TBL] [Abstract][Full Text] [Related]
14. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration.
Krieter DH; Hackl A; Rodriguez A; Chenine L; Moragues HL; Lemke HD; Wanner C; Canaud B
Nephrol Dial Transplant; 2010 Jan; 25(1):212-8. PubMed ID: 19755476
[TBL] [Abstract][Full Text] [Related]
15. Removal of vancomycin administered during dialysis by a high-flux dialyzer.
Nyman HA; Agarwal A; Senekjian HO; Leypoldt JK; Cheung AK
Hemodial Int; 2018 Jul; 22(3):383-387. PubMed ID: 29380499
[TBL] [Abstract][Full Text] [Related]
16. β-trace protein is highly removed during haemodialysis with high-flux and super high-flux membranes.
Donadio C; Tognotti D; Caponi L; Paolicchi A
BMC Nephrol; 2017 Feb; 18(1):68. PubMed ID: 28219328
[TBL] [Abstract][Full Text] [Related]
17. Relationship between dialyser type and signs and symptoms.
Levin NW; Zasuwa G
Nephrol Dial Transplant; 1993; 8 Suppl 2():30-9. PubMed ID: 8272250
[TBL] [Abstract][Full Text] [Related]
18. Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.
Zoer J; Schrander-van der Meer AM; van Dorp WT
Pharm World Sci; 1997 Aug; 19(4):191-6. PubMed ID: 9297732
[TBL] [Abstract][Full Text] [Related]
19. A pilot study comparing the efficiency of a novel asymmetric cellulose triacetate (ATA) dialyser membrane (Solacea-190H) to a standard high flux polysulfone dialyser membrane (FX-80) in the setting of extended hours haemodialysis.
Kameshwar K; Damasiewicz MJ; Polkinghorne KR; Kerr PG
Nephrology (Carlton); 2022 Jun; 27(6):494-500. PubMed ID: 35195932
[TBL] [Abstract][Full Text] [Related]
20. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.
Ariano RE; Fine A; Sitar DS; Rexrode S; Zelenitsky SA
Am J Kidney Dis; 2005 Oct; 46(4):681-7. PubMed ID: 16183423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
